Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06724653

Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

Study start date is on Nov 27th 2024.

A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Heart Failure Cardiovascular Diseases Ejection Fraction Heart Diseases Recovery of Function

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jeonbuk national university hospital, Jeonju, Jeollabuk-do, South Korea

Loading trial locations.

About this study

Patients described above randomly assigned to drug tapering group and drug maintaining group.

Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group.

Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • initial echocardiogram ejection fraction less than 40%
  • follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
  • NTprobnp criteria
  • eGFR ≥60 ; less 440
  • eGFR 45-59: less 980
  • eGFR 30-44; less 1220
  • eGFR < 30 : less 5300
  • in HD; no criteria for NTproBNP
  • on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)

Exclusion criteria

  • under age 18 year
  • uncontrolled BP ( over 150/90)
  • coronary revascularization within 6 months
  • significant valve disease
  • arrhythmia requiring rate control
  • CKD with albuminuria ( over 30mg/g)
  • Pregnancy

Treatment and study plan

RAS blocker tapering group

Drug

RAS blocker tapering out

Beta blocker tapering out

Drug

Beta blocker tapering out group

Primary outcomes

  1. Heart failure relapse

    Time frame: From enrollment to the end of treatment at 18 months

    LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m^2

Study contacts

Contact information is provided by the study sponsor or research team.

Yujin Yang

CONTACT

[email protected]

821043311245

Sponsors and collaborators

Lead sponsor

Chungnam National University Hospital

Other

Registry information

Acronym: HFrecEF

Important dates

Study start
2025
Primary completion
2025
Study completion
2027
First posted
Dec 9, 2024
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.